← Leaderboards
Martin Devenport
Oncoimmune, Inc.
$1,988,729
Attributed
$5,316,416
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2017–20$2M$1.5M$1M$500K$0
'17
'18
'19
'20
Funding mix
By agency
NIH$5,316,416 · 3
By mechanism
R44$5,003,702 · 2
R41$312,714 · 1
Top collaborators
- Yang Liu3 shared
- Pavan Reddy3 shared
- Pan Zheng3 shared
- Steven M. Devine1 shared
- Toshihiko Tanno1 shared
Others in their field
Other Emerging Leaders on “Dose”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Beth Baseler · Leidos Biomedical Research, Inc.$52,807,683
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Paula Gonzalez-Maya · Fundacion Inciensa$37,578,679
- Xinhua Li · Nano Terra, Inc.$35,520,438
- Jeffrey Reich · Sparian Biosciences, Inc.$28,575,028
Research focus
DoseHigh RiskInflammationClinical TrialsLeukemiaMolecularPlacebosPatternRandomizedAdultHematopoietic Stem Cell TransplantationDouble-Blind MethodInfectionPre-Clinical ModelAcute Graft Versus Host DiseaseCurative TreatmentsAffectGraft Vs Leukemia EffectDesignClinical DevelopmentChimeric ProteinsAllogenicBaseCells
Grant awards (7)
SAC-COVID: An FDA-approved Phase III clinical trial evaluating the safety and therapeutic efficacy of CD24Fc in severe COVID-19 patients$1,000,000
R44 · FY2020 · CA
A phase II dose expansion clinical trial testing the efficacy of CD24Fc for the prophylaxis of severe graft vs host disease and leukemia relapse$985,075
R44 · FY2020 · CA
A phase II dose expansion clinical trial testing the efficacy of CD24Fc for the prophylaxis of severe graft vs host disease and leukemia relapse$1,014,321
R44 · FY2019 · CA
Evaluation of therapeutic efficacy and safety of novel small RNA target delivery platform in vivo.$312,714
R41 · FY2019 · OD · contact PI
A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease.$982,509
R44 · FY2018 · CA · contact PI
A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease.$4,319
R44 · FY2018 · CA · contact PI
A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease.$1,017,478
R44 · FY2017 · CA · contact PI